Top

Published in:

03-06-2022 | Obesity | Original Article

Insulin resistance and cardiometabolic indexes: comparison of concordance in working-age subjects with overweight and obesity

Authors: Luisella Vigna, Amedea Silvia Tirelli, Melania Gaggini, Salvina Di Piazza, Laura Tomaino, Stefano Turolo, Gianluca Moroncini, Kyriazoula Chatzianagnostou, Fabrizia Bamonti, Cristina Vassalle

Published in: Endocrine | Issue 2/2022

Abstract

Purpose

The aim of the study was to evaluate indexes of insulin resistance and cardiometabolic risk in a large population of workers with overweight or obesity, in order to identify a possible efficient, cheap and simple strategy to apply in workers’ health surveillance.

Methods

The evaluation of IR and cardiometabolic risk indexes (HOMA, QUICKI, Ty/HDLC, TyG, insuTAG, Castelli risk indexes 1 and 2, non-HDLC, TRL-C, AIP, and VAI) was performed in a population of 1195 working-age subjects with overweight or obesity (322 males, mean age 49 ± 11 years).

Results

The prevalence of IR and cardiometabolic risk was higher among males for all indexes. Aging, waist circumference, BMI, blood pressure, glucose, CRP, fibrinogen and uric acid were correlated more frequently with IR/cardiometabolic indexes in women, homocysteine in men. The percentage of the workers identified as insulin resistant (IR+) or at higher cardiometabolic risk greatly vary according to the different index used.

Conclusion

With a small group of biomarkers and anthropometric measures (fasting glucose and insulin, lipid profile, BMI and waist circumference) is possible to calculate a number of IR/cardiometabolic indexes, which, likely reflecting different pathophysiological aspects also related to gender, might help in a personalized evaluation of IR and cardiometabolic risk.

R.H. Eckel, S.E. Kahn, E. Ferrannini, A.B. Goldfine, D.M. Nathan, M.W. Schwartz, R.J., S.R. Smith, Obesity and type 2 diabetes: what Can be unified and what needs to be individualized? Diabetes Care 34 (2011). https://doi.org/10.2337/dc11-0447.

J.P. Moriarty, M.E. Branda, K.D. Olsen, N.D. Shah, B.J. Borah, A.E. Wagie, J.S. Egginton, J.M. Naessens, The effects of incremental costs of smoking and obesity on health care costs among adults: a 7-year longitudinal study. J. Occup. Environ. Med. 54 (2012). https://doi.org/10.1097/JOM.0b013e318246f1f4.

M.S. Greenfield, L. Doberne, F. Kraemer, T. Tobey, G. Reaven. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes. 30 (1981). https://doi.org/10.2337/diab.30.5.387.

R.A. DeFronzo, J.D. Tobin, R. Andres, Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. Endocrinol. Metab. Gastrointest. Physiol. 6 (1979). https://doi.org/10.1152/ajpendo.1979.237.3.e214.

D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, R.C. Turner. Homeostasis model assessment: insulin resis tance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985). https://doi.org/10.1007/BF00280883.

A. Katz, S.S. Nambi, K. Mather, A.D. Baron, D.A. Follmann, G. Sullivan, M.J. Quon, Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab. 85 (2000). https://doi.org/10.1210/jcem.85.7.6661.

M. Gutt, C.L. Davis, S.B. Spitzer, M.M. Llabre, M. Kumar, E.M. Czarnecki, N. Schneiderman, J.S. Skyler, J.B. Marks, Validation of the insulin sensitivity index (ISI0,120): Comparison with other measures. Diabetes Res. Clin. Pract. 47 (2000). https://doi.org/10.1016/S0168-8227(99)00116-3.

F. Tosi, E. Bonora, P. Moghetti, Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum. Reprod. 32 (2017) https://doi.org/10.1093/humrep/dex308.

T. McLaughlin, G. Reaven, F. Abbasi, C. Lamendola, M. Saad, D. Waters, J. Simon, R.M. Krauss. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am. J. Cardiol. 96 (2005). https://doi.org/10.1016/j.amjcard.2005.03.085.

10.

R. Quispe, R.J. Manalac, K.F. Faridi, M.J. Blaha, P.P. Toth, K.R. Kulkarni, K. Nasir, S.S. Virani, M. Banach, R.S. Blumenthal et al. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study. Atherosclerosis 242 (2015). https://doi.org/10.1016/j.atherosclerosis.2015.06.057.

11.

S.H. Lee, H.S. Kwon, Y.M. Park, H.S. Ha, S.H. Jeong, H.K. Yang, J.H. Lee, H.W. Yim, M. Il Kang; W.C. Lee et al. Predicting the development of diabetes using the product of triglycerides and glucose: the chungju metabolic disease cohort (CMC) study. PLoS ONE 9 (2014). https://doi.org/10.1371/journal.pone.0090430.

12.

R.N. Thota, K.A. Abbott, J.J.A. Ferguson, M. Veysey, M. Lucock, S. Niblett, K. King, M.L. Garg, InsuTAG: a novel physiologically relevant predictor for insulin resistance and metabolic syndrome. Sci. Rep. 7 (2017). https://doi.org/10.1038/s41598-017-15460-z.

13.

W.P. Castelli, R.D. Abbott, P.M. McNamara, Summary estimates of cholesterol used to predict coronary heart disease. Circulation 67 (1983). https://doi.org/10.1161/01.CIR.67.4.730.

14.

X. Su, Y. Kong, D. Peng, Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids Health Dis. 18 (2019). https://doi.org/10.1186/s12944-019-1080-x.

15.

M. Dobiásová AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 52 (2006).

16.

M.C. Amato, C. Giordano, Visceral adiposity index: an indicator of adipose tissue dysfunction. Int. J. Endocrinol. (2014). https://doi.org/10.1155/2014/730827.

17.

L. Vigna, C. Vassalle, A.S. Tirelli, F. Gori, L. Tomaino, L. Sabatino, F. Bamonti, Gender-related association between uric acid, homocysteine, γ-glutamyltransferase, inflammatory biomarkers and metabolic syndrome in subjects affected by obesity. Biomark. Med. 11 (2017). https://doi.org/10.2217/bmm-2017-0072.

18.

A. Borai, C. Livingstone, I. Kaddam, G. Ferns. Selection of the appropriate method for the assessment of insulin resistance. BMC Med. Res. Methodol. 11 (2011). https://doi.org/10.1186/1471-2288-11-158.

19.

R. Muniyappa, S. Lee, H. Chen, M.J. Quon, Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. Am. J. Physiol. - Endocrinol. Metab. 294 (2008). https://doi.org/10.1152/ajpendo.00645.2007.

20.

L.E. Simental-Mendía, M. Rodríguez-Morán, F. Guerrero-Romero, The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab. Syndr. Relat. Disord. 6 (2008). https://doi.org/10.1089/met.2008.0034.

21.

F. Guerrero-Romero, L.E. Simental-Mendía, M. González-Ortiz, E. Martínez-Abundis, M.G. Ramos-Zavala, S.O. Hernández-González, O. Jacques-Camarena, M. Rodríguez-Morán, The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J. Clin. Endocrinol. Metab. 95 (2010). https://doi.org/10.1210/jc.2010-0288.

22.

F. Lucatello, L. Vigna, M. Carugno, A.S. Tirelli, P.A. Bertazzi, L. Riboldi, Comparison of indexes for assessing insulin resistance for the health surveillance among workers [Confronto tra indici per la valutazione dell’insulino-resistenza nella sorveglianza sanitaria dei lavoratori]. G. Ital. Med. Lav. Ergon. 34 (2012).

23.

N. Ahn, S.E. Baumeister, U. Amann, W. Rathmann, A. Peters, C. Huth, B. Thorand, C. Meisinger, Visceral adiposity index (VAI), lipid accumulation product (LAP), and product of triglycerides and glucose (TyG) to discriminate prediabetes and diabetes. Sci. Rep. 9 (2019). https://doi.org/10.1038/s41598-019-46187-8.

24.

J. Millán, X. Pintó, A. Muñoz, M. Zúñiga, J. Rubiés-Prat, L.F. Pallardo, L. Masana, A. Mangas, A. Hernández-Mijares, P. González-Santos, J.F. Ascaso, J. Pedro-Botet, Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc. Health Risk Manag. 5 (2009). https://doi.org/10.2147/vhrm.s6269.

25.

W. Masson, M. Lobo, D. Siniawski, G. Molinero, M. Huerín, J.P. Nogueira, Impact of lipid-lowering therapy on mortality according to the baseline non-HDL cholesterol level: a meta-analysis. High Blood Press. Cardiovasc. Prev. 26 (2019). https://doi.org/10.1007/s40292-019-00330-8.

26.

A. Varbo, M. Benn, A. Tybjærg-Hansen, B.G. Nordestgaard, Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 128 (2013). https://doi.org/10.1161/CIRCULATIONAHA.113.003008.

27.

O. Castañer, X. Pintó, I. Subirana, A.J. Amor, E. Ros, Á. Hernáez, M.Á. Martínez-González, D. Corella, J. Salas-Salvadó, R. Estruch et al. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J. Am. Coll. Cardiol. 76 (2020). https://doi.org/10.1016/j.jacc.2020.10.008.

28.

M. Dobiášová, J. Frohlich, The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate inapob-lipoprotein-depleted plasma (FERHDL). Clin. Biochem. 34 (2001). https://doi.org/10.1016/S0009-9120(01)00263-6.

29.

E. Al Shawaf, E. Al-Ozairi, F. Al-Asfar, A. Mohammad, S. Al-Beloushi, S. Devarajan, F. Al-Mulla, J. Abubaker, H. Arefanian, Atherogenic index of plasma (AIP) a tool to assess changes in cardiovascular disease risk post laparoscopic sleeve gastrectomy. J. Diabetes Res. 2020 (2020). https://doi.org/10.1155/2020/2091341.

30.

H. King, M. Rewers, Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 16 (1993). https://doi.org/10.2337/diacare.16.1.157.

31.

V. Regitz-Zagrosek, E. Lehmkuhl, M.O. Weickert, Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin. Res. Cardiol. 95 (2006) https://doi.org/10.1007/s00392-006-0377-8.

32.

A.G. Huebschmann, R.R. Huxley, W.M. Kohrt, P. Zeitler, J.G. Regensteiner, J.E.B. Reusch, Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia 62 (2019). https://doi.org/10.1007/s00125-019-4939-5.

33.

J. Logue, J. J. Walker, H.M. Colhoun, G.P. Leese, R.S. Lindsay, J.A. McKnight, A.D. Morris, D.W. Pearson, J.R. Petrie, S. Philip et al. Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia 54 (2011). https://doi.org/10.1007/s00125-011-2313-3.

34.

S. Paul, G. Thomas, A. Majeed, K. Khunti, K. Klein, Women develop type 2 diabetes at a higher body mass index than men. Diabetologia 55, 1556–7 (2012).CrossRef

35.

N. Sattar, Gender aspects in type 2 diabetes mellitus and cardiometabolic risk. Best Pract. Res. Clin. Endocrinol. Metab. 27 (2013). https://doi.org/10.1007/s00125-012-2496-2.

36.

M.K. Breyer, A. Ofenheimer, J. Altziebler, S. Hartl, O.C. Burghuber, M. Studnicka, D. Purin, C. Heinzle, H. Drexel, F.M.E. Franssen et al. Marked differences in prediabetes- and diabetes-associated comorbidities between men and women—Epidemiological results from a general population-based cohort aged 6-80 years—The LEAD (Lung, hEart, sociAl, boDy) study. Eur. J. Clin. Investig. 50 (2020). https://doi.org/10.1111/eci.13207.

37.

A. Al-Salameh, P. Chanson, S. Bucher, V. Ringa L. Becquemont. Cardiovascular disease in type 2 diabetes: a review of sex-related differences in predisposition and prevention. Mayo Clin. Proc. 94(2) (2019). https://doi.org/10.1016/j.mayocp.2018.08.007.

38.

V. Grossmannm, V.H. Schmitt, T. Zeller, M. Panova-Noeva, A. Schulz, D. Laubert-Reh, C. Juenger, R.B. Schnabel, T.G.J. Abt, R. Laskowski, J. Wiltink, E. Schulz, S. Blankenberg, K.J. Lackner, T. Münzel, PWild, P.S. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care 38 (2015). https://doi.org/10.2337/dc14-3008.

39.

J. Dierkes, A. Jeckel, A. Ambrosch, S. Westphal, C. Luley, H. Boeing, Factors explaining the difference of total homocysteine between men and women in the European investigation into cancer and nutrition potsdam study. Metabolism. 50 (2001) https://doi.org/10.1053/meta.2001.23286.

40.

S. Pitla, B. Nagalla, Gender-related differences in the relationship between plasma homocysteine, anthropometric and conventional biochemical coronary heart disease risk factors in middle-aged indians. Ann. Nutr. Metab. 54 (2009). https://doi.org/10.1159/000199452.

41.

B. Vogel, M. Acevedo, Y. Appelman, C.N. Bairey Merz, A. Chieffo, G.A. Figtree, M. Guerrero, V. Kunadian, C.S.P. Lam, A.H.E.M. Maas, A.S. Mihailidou, A. Olszanecka, J.E. Poole, C. Saldarriaga, J. Saw, J., Zühlke, R. Mehran, The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 19 (2021). https://doi.org/10.1016/S0140-6736(21)00684-X.

42.

C. Vassalle, T. Simoncini, P. Chedraui, F.R. Pérez-López, Why sex matters: the biological mechanisms of cardiovascular disease. Gynecol. Endocrinol. 28(9), 746–751 (2012). https://doi.org/10.3109/09513590.2011.652720.CrossRefPubMed

43.

C. Vassalle, R. Sciarrino, S. Bianchi, D. Battaglia, A. Mercuri, S. Maffei, Sex-related differences in association of oxidative stress status with coronary artery disease. Fertil. Steril. 97(2), 414–419 (2012). https://doi.org/10.1016/j.fertnstert.2011.11.045.CrossRefPubMed

44.

M. Amiri, I. Karabegović, A.C. van Westing, A.J.C.F. Verkaar, S. Beigrezaei, M. Lara, W.M. Bramer, T. Voortman, Whole-diet interventions and cardiovascular risk factors in postmenopausal women: a systematic review of controlled clinical trials. Maturitas 155, 40–53 (2022). https://doi.org/10.1016/j.maturitas.2021.10.001.CrossRefPubMed

45.

S. Sciomer, F. Moscucci, S. Maffei, S. Gallina, A.V. Mattioli, Prevention of cardiovascular risk factors in women: The lifestyle paradox and stereotypes we need to defeat. Eur. J. Prev. Cardiol. 26(6), 609–610 (2019). https://doi.org/10.1177/2047487318810560.CrossRefPubMed

46.

M. D’Adamo, L. Perego, M. Cardellini, M.A. Marini, S. Frontoni, F. Andreozzi, A. Sciacqua, D. Lauro, P. Sbraccia, M. Federici et al. The -866A/A genotype in the promoter of the human uncoupling protein 2 gene is associated with insulin resistance and increased risk of type 2 diabetes. Diabetes 53 (2004) https://doi.org/10.2337/diabetes.53.7.1905.

47.

C. Capurso, A. Capurso. From excess adiposity to insulin resistance: the role of free fatty acids. Vascul. Pharmacol. 57 (2012). https://doi.org/10.1016/j.vph.2012.05.003.

48.

G. Riccardi, R. Giacco, A.A. Rivellese, Dietary fat, insulin sensitivity and the metabolic syndrome. Clin. Nutr. 23 (2004). https://doi.org/10.1016/j.clnu.2004.02.006.

49.

M.S. Zhou, I.H. Schulman, Q. Zeng, Link between the renin-angiotensin system and insulin resistance: Implications for cardiovascular disease. Vasc. Med. 17 (2012). https://doi.org/10.1177/1358863X12450094.

50.

ME. Lindholm, F. Marabita, D. Gomez-Cabrero, H. Rundqvist, TJ. Ekström, J. Tegnér, CJ. Sundberg, An integrative analysis reveals coordinated reprogramming of the epigenome and the transcriptome in human skeletal muscle after training. Epigenetics 9, 1557–69 (2014).CrossRef

51.

S. Placzkowska, L. Pawlik-Sobecka, I. Kokot, A. Piwowar, Indirect insulin resistance detection: current clinical trends and laboratory limitations. Biomed. Pap. 163 (2019). https://doi.org/10.5507/bp.2019.021.

Title: Insulin resistance and cardiometabolic indexes: comparison of concordance in working-age subjects with overweight and obesity
Authors: Luisella Vigna
Amedea Silvia Tirelli
Melania Gaggini
Salvina Di Piazza
Laura Tomaino
Stefano Turolo
Gianluca Moroncini
Kyriazoula Chatzianagnostou
Fabrizia Bamonti
Cristina Vassalle
Publication date: 03-06-2022
Publisher: Springer US
Keywords: Obesity
Obesity
Insulins
Overweight
Insulins
Published in: Endocrine / Issue 2/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-022-03087-8

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2022

Risk stratification in patients with anaplastic thyroid carcinoma: role of age

Association between glycemic control and the outcome in hospitalized patients with COVID-19

“Lymphocyte population in peripheral blood in children and adolescents with graves disease. Potential predictive tool for severity of the disease”

Long-term follow-up ultrasonography surveillance in a large cohort of patients with papillary thyroid carcinoma

Vertebral fractures at hospitalization predict impaired respiratory function during follow-up of COVID-19 survivors

Resistant prolactinomas: a case series of 26 patients

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage